"What we found was a very different frequency of alterations in important genes," says Camilo Arenas-Gallo, MD.
In this video, Camilo Arenas-Gallo, MD, discusses findings from the study, “Prostate Cancer Genetic Alterations in Hispanic Men,” which were presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Arenas-Gallo is a research fellow at Case Western Reserve University in Cleveland, Ohio.
Video Transcript:
What we did is, compiling this data that is publicly available, as I said in GENIE, [we tried] to [look at] Hispanic Whites [and] Hispanic Blacks, compared to non-Hispanic Whites and non-Hispanic Black men. Unfortunately, the database doesn't have a lot of Hispanic Blacks, so we had to remove that from our dataset. So, it's mostly self-identified Hispanic White men.
What we found was a very different frequency of alterations in important genes. For example, DNA genes that do DNA repair or genes that have been correlated with worse outcomes in men with prostate cancer. We found interesting differences between the Hispanic population with non-Hispanic Whites and Blacks, but we also found very interesting similarities. Probably the most important is that the actionable mutations that you can actually develop drugs or target therapies [from] is very similar. We didn't find any significant differences, which means that developing a targeted therapies is going to be beneficial for a high percentage of Hispanic men.
This transcription has been edited for clarity.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.